Carphenazine

Summary

Carphenazine (CHEMBL1201328) is an approved small-molecule dopaminergic antagonist.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 425.6 Da · C24H31N3O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201328
Name	Carphenazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	18104
ChEBI	CHEBI:51235
Molecular formula	C24H31N3O2S
Molecular weight	425.6
InChIKey	XZSMZRXAEFNJCU-UHFFFAOYSA-N

SMILES: CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO

IUPAC name: 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one

ChEBI definition: A member of the class of phenothiazines that is 10H-phenothiazine which carries a propanoyl group at position 2 and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at position N-10. It is an antipsychotic drug that is used for the treatment of chronic schizophrenia.

Pharmacological roles (ChEBI): dopaminergic antagonist, antiemetic, phenothiazine antipsychotic drug.

Also known as: Carfenazina, Carfenazine, Carphenazine, SID50125832, CARFENAZINE, CARPHENAZINE

Parent form; salt/anhydrous children: CHEMBL2358147

Patent coverage: 485 distinct patent families (1,858 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Nuclear receptor ROR-gamma, 4’-phosphopantetheinyl transferase ffp.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P51450	5.3	Potency	5012	nM	CHEMBL_ACT_4976277

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).